amifostine anhydrous has been researched along with Experimental Mammary Neoplasms in 13 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| " These pre-clinical findings provide proof-of-principle to further delineate specific mechanisms underlying amifostine's beneficial effects, determine optimal amifostine-radiation therapy dosing regimens, and thereby expedite translation into clinical trials to reduce lymphedema incidence and severity in cancer patients at high lymphedema risk in whom radiation therapy is the recommended therapy." | 1.36 | Radioprotection from radiation-induced lymphedema without tumor protection. ( Bernas, MJ; Bracamonte, F; Daley, SK; Hirleman, ED; McKenna, M; Stea, BD; Stejskal, A; Witte, MH, 2010) |
| "Cysteamine treatment increased the development of ER-negative tumors." | 1.31 | Inhibitory effects of WR-2721 and cysteamine on tumor initiation in mammary glands of pregnant rats by radiation. ( Inano, H; Kobayashi, H; Onoda, M; Suzuki, K; Wakabayashi, K, 2000) |
| " Skin reactions, four different kidney assays, regrowth delay and local control of tumours have been used to construct dose-response curves from which the degree of radioprotection can be quantified as a protection factor." | 1.27 | Fractionation studies with WR-2721: normal tissues and tumour. ( Denekamp, J; Rojas, A; Smith, KA; Soranson, JA; Stewart, FA, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (69.23) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daley, SK | 1 |
| Bernas, MJ | 1 |
| Stea, BD | 1 |
| Bracamonte, F | 1 |
| McKenna, M | 1 |
| Stejskal, A | 1 |
| Hirleman, ED | 1 |
| Witte, MH | 1 |
| Cassatt, DR | 1 |
| Fazenbaker, CA | 1 |
| Bachy, CM | 1 |
| Kifle, G | 1 |
| McCarthy, MP | 1 |
| Yuhas, JM | 3 |
| Spellman, JM | 1 |
| Jordan, SW | 1 |
| Pardini, MC | 1 |
| Afzal, SM | 1 |
| Culo, F | 1 |
| Stewart, FA | 2 |
| Rojas, A | 2 |
| Denekamp, J | 2 |
| Begg, AC | 1 |
| Terry, NH | 1 |
| Tsukiyama, I | 1 |
| Tanaka, Y | 1 |
| Akagi, K | 1 |
| Hasegawa, T | 1 |
| Nakazawa, M | 1 |
| Harima, K | 1 |
| Murata, T | 1 |
| Sawada, S | 1 |
| Inano, H | 2 |
| Onoda, M | 2 |
| Suzuki, K | 2 |
| Kobayashi, H | 2 |
| Wakabayashi, K | 2 |
| Lespinasse, F | 1 |
| Oiry, J | 1 |
| Fatome, M | 1 |
| Ardouin, P | 1 |
| Imbach, J | 1 |
| Malaise, EP | 1 |
| Guichard, M | 1 |
| Soranson, JA | 1 |
| Smith, KA | 1 |
13 other studies available for amifostine anhydrous and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Radioprotection from radiation-induced lymphedema without tumor protection.
Topics: Amifostine; Animals; Colony-Forming Units Assay; Female; Humans; Incidence; Lymphatic Vessels; Lymph | 2010 |
Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure.
Topics: Amifostine; Animals; Dose Fractionation, Radiation; Drug Evaluation, Preclinical; Female; Injections | 2005 |
Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid.
Topics: Absorption; Adenocarcinoma; Amifostine; Animals; Carcinoma, Squamous Cell; Female; Liver; Mammary Ne | 1980 |
A more general role for WR-2721 in cancer therapy.
Topics: Amifostine; Animals; Cisplatin; Female; Mammary Neoplasms, Experimental; Neoplasms; Organothiophosph | 1980 |
Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide.
Topics: Amifostine; Animals; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combin | 1980 |
Radioprotection of two mouse tumors by WR-2721 in single and fractionated treatments.
Topics: Amifostine; Animals; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female | 1983 |
Modification of stromal radiosensitivity by misonidazole and WR-2721.
Topics: Adenocarcinoma; Amifostine; Animals; Connective Tissue; Dose-Response Relationship, Radiation; Male; | 1983 |
[Combined use of amifostine and misonidazole in experimental radiotherapy].
Topics: Amifostine; Animals; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Misonidazole; Ni | 1983 |
[Studies on the radioprotective effects of YM-08310 (= WR-2721) Part 1: Radioprotective effects of YM-08310 on normal and malignant tissues in mice].
Topics: Amifostine; Animals; Esophagus; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Organothi | 1983 |
Inhibitory effects of WR-2721 and cysteamine on tumor initiation in mammary glands of pregnant rats by radiation.
Topics: Adenocarcinoma; Amifostine; Animals; Body Weight; Cysteamine; Dose-Response Relationship, Radiation; | 2000 |
Prevention of radiation-induced mammary tumours in rats by combined use of WR-2721 and tamoxifen.
Topics: Amifostine; Animals; Antineoplastic Agents, Hormonal; Drug Therapy, Combination; Female; Mammary Neo | 2000 |
Radioprotection of EMT6 tumor by a new class of radioprotectors based on a pseudo-peptide cysteamine combination.
Topics: Amifostine; Animals; Bone Marrow; Cell Line; Cell Survival; Cysteamine; Gamma Rays; Hematopoiesis; L | 1985 |
Fractionation studies with WR-2721: normal tissues and tumour.
Topics: Amifostine; Animals; Carcinoma; Female; Kidney; Lethal Dose 50; Mammary Neoplasms, Experimental; Mic | 1986 |